Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Perspective Therapeutics, Inc. is advancing its radiopharmaceutical development for cancer treatments and will present at the upcoming J.P. Morgan Healthcare Conference [1][2]. Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceuticals, focusing on innovative cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2]. - The company is developing complementary imaging diagnostics that utilize the same targeting moieties, enhancing personalized treatment and patient outcomes through a "theranostic" approach [2]. Clinical Programs - The company's clinical programs include neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359), which are currently in Phase 1/2a imaging and therapy trials in the U.S. [3]. - Perspective is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3].